uniQure N.V. Operating Expenses
uniQure N.V. (QURE) reported Operating Expenses of $28.60 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-04-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2019-04-29
- uniQure N.V. operating expenses for the quarter ending 2019-03-31 was $28.60M, a 22.45% increase year-over-year.
- uniQure N.V. operating expenses for the quarter ending 2018-12-31 was $25.93M, a 1.71% increase year-over-year.
- uniQure N.V. operating expenses for the quarter ending 2018-09-30 was $26.44M, a 2.93% increase year-over-year.
- uniQure N.V. operating expenses for the quarter ending 2018-06-30 was $24.39M, a 9.49% increase year-over-year.
- uniQure N.V. operating expenses for fiscal 2018 was $100.11M, a 3.42% increase from fiscal 2017.
- uniQure N.V. operating expenses for fiscal 2017 was $96.81M, a 1.73% decline from fiscal 2016.
- uniQure N.V. operating expenses for fiscal 2016 was $98.51M, a 19.39% increase from fiscal 2015.
- uniQure N.V. operating expenses for fiscal 2015 was $82.51M, a 35.60% increase from fiscal 2014.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2019-03-31 | $28.60M 10-Q · filed 2019-04-29 | $54.53M derived: sum of 2 quarters · filed 2019-04-29 | $80.97M derived: sum of 3 quarters · filed 2019-04-29 | $105.36M derived: sum of 4 quarters · filed 2019-04-29 |
| 2018-12-31 | $25.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $52.37M derived: sum of 2 quarters · filed 2019-02-28 | $76.75M derived: sum of 3 quarters · filed 2019-02-28 | $100.11M 10-K · filed 2019-02-28 |
| 2018-09-30 | $26.44M 10-Q · filed 2018-11-06 | $50.83M derived: sum of 2 quarters · filed 2018-11-06 | $74.19M 10-Q · filed 2018-11-06 | $99.68M derived: sum of 4 quarters · filed 2019-04-29 |
| 2018-06-30 | $24.39M 10-Q · filed 2018-08-08 | $47.75M 10-Q · filed 2018-08-08 | $73.24M derived: sum of 3 quarters · filed 2019-04-29 | $98.93M derived: sum of 4 quarters · filed 2019-04-29 |
| 2018-03-31 | $23.36M 10-Q · filed 2019-04-29 | $48.85M derived: sum of 2 quarters · filed 2019-04-29 | $74.54M derived: sum of 3 quarters · filed 2019-04-29 | $96.81M derived: sum of 4 quarters · filed 2019-04-29 |
| 2017-12-31 | $25.49M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $51.18M derived: sum of 2 quarters · filed 2019-02-28 | $73.45M derived: sum of 3 quarters · filed 2019-02-28 | $96.81M 10-K · filed 2019-02-28 |
| 2017-09-30 | $25.69M 10-Q · filed 2018-11-06 | $47.96M derived: sum of 2 quarters · filed 2018-11-06 | $71.31M 10-Q · filed 2018-11-06 | $97.05M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $22.28M 10-Q · filed 2018-08-08 | $45.63M 10-Q · filed 2018-08-08 | $71.36M derived: sum of 3 quarters · filed 2019-02-28 | $93.08M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $23.35M 10-Q · filed 2018-04-30 | $49.09M derived: sum of 2 quarters · filed 2019-02-28 | $70.80M derived: sum of 3 quarters · filed 2019-02-28 | $97.86M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $25.73M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $47.45M derived: sum of 2 quarters · filed 2019-02-28 | $74.50M derived: sum of 3 quarters · filed 2019-02-28 | $98.51M 10-K · filed 2019-02-28 |
| 2016-09-30 | $21.72M 10-Q · filed 2017-11-01 | $48.77M derived: sum of 2 quarters · filed 2017-11-01 | $72.78M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $27.05M 10-Q · filed 2017-08-08 | $51.06M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $24.00M 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $82.51M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $60.84M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |